{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T06:25:24Z","timestamp":1786947924462,"version":"build-2736575974"},"reference-count":126,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T00:00:00Z","timestamp":1786838400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T00:00:00Z","timestamp":1786838400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clin Pharma and Therapeutics"],"abstract":"<jats:p>The comprehensive understanding of triplet repeat expansion (TRE) disorders as monogenic neurodegenerative diseases presents a fundamental challenge for developing treatments capable of modifying the disease course, as neurogenetic research indicates. The past 30\u2009years reveal that preclinical results demonstrating strong effectiveness have not translated into success in human clinical trials, with multiple phase II and III studies for polyglutamine and non\u2010coding, loss\u2010of\u2010function repeat disorders yielding unfavorable outcomes. This review emphasizes that clinical systems, which measure target engagement do not generate effective outcomes for these TRE neurodegenerative conditions. We highlight that these failures arise not from a fundamental misunderstanding of the underlying genetic mutations, but from recurring methodological and pharmacological limitations across the translational pipeline. The main reasons for these unsuccessful clinical trials include two factors: the necessity for clinicians to monitor pharmacodynamic biomarkers indicating central nervous system target engagement, and the reliance on traditional clinical rating scales that linearly assess disease progression in patients with complex medical conditions. The use of non\u2010selective gene silencing methods can lead to unexpected toxic effects, especially when treatments begin after patients reach an advanced disease stage, causing irreversible brain cell damage. The field of precision neurogenetics must advocate for future trials to employ objective fluid and digital biomarkers, utilize allele\u2010specific treatments, and prioritize patients who have not yet experienced severe brain cell loss. We further propose evidence\u2010based design principles to improve the probability of clinical success in future TRE disease trials.<\/jats:p>","DOI":"10.1002\/cpt.70445","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T05:59:22Z","timestamp":1786946362000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Translational Paradox of Triplet Repeat Expansion Disorders: Synthesizing Clinical Trial Failures to Guide Future Therapeutics"],"prefix":"10.1002","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0759-7818","authenticated-orcid":false,"given":"Vishnu","family":"Swarup","sequence":"first","affiliation":[{"name":"Department of Neurology All India Institute of Medical Sciences  New Delhi India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1101-403X","authenticated-orcid":false,"given":"Deepika","family":"Deepika","sequence":"additional","affiliation":[{"name":"Department of Neurology All India Institute of Medical Sciences  New Delhi India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0532-3370","authenticated-orcid":false,"given":"Divyani","family":"Garg","sequence":"additional","affiliation":[{"name":"Department of Neurology All India Institute of Medical Sciences  New Delhi India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4590-7947","authenticated-orcid":false,"given":"Achal Kumar","family":"Srivastava","sequence":"additional","affiliation":[{"name":"Department of Neurology All India Institute of Medical Sciences  New Delhi India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,8,16]]},"reference":[{"key":"e_1_2_5_1_1","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1136\/pn-2023-003938","article-title":"Repeat expansion disorders","volume":"25","author":"Chen Z.","year":"2025","journal-title":"Pract. Neurol."},{"key":"e_1_2_5_2_1","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/B978-0-444-63233-3.00009-9","article-title":"Repeat expansion diseases","volume":"147","author":"Paulson H.","year":"2018","journal-title":"Handb. Clin. Neurol."},{"key":"e_1_2_5_3_1","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1021\/acs.biochem.6b00936","article-title":"Proteins containing expanded Polyglutamine tracts and neurodegenerative disease","volume":"56","author":"Adegbuyiro A.","year":"2017","journal-title":"Biochemistry"},{"key":"e_1_2_5_4_1","doi-asserted-by":"crossref","first-page":"7815","DOI":"10.1038\/s41598-021-87382-w","article-title":"PolyQ\u2010expanded proteins impair cellular proteostasis of ataxin\u20103 through sequestering the co\u2010chaperone HSJ1 into aggregates","volume":"11","author":"Yue H.\u2010W.","year":"2021","journal-title":"Sci. Rep."},{"key":"e_1_2_5_5_1","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41580-021-00382-6","article-title":"Molecular mechanisms underlying nucleotide repeat expansion disorders","volume":"22","author":"Malik I.","year":"2021","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"e_1_2_5_6_1","volume-title":"StatPearls","author":"Ramakrishnan S.","year":"2026"},{"key":"e_1_2_5_7_1","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2024.1432444","article-title":"Epigenetic insights into fragile X syndrome","volume":"12","author":"Xie L.","year":"2024","journal-title":"Front. Cell Dev. Biol."},{"issue":"1","key":"e_1_2_5_8_1","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/jnc.12254","article-title":"Gene regulation and epigenetics in Friedreich's ataxia","volume":"126","author":"Yandim C.","year":"2013","journal-title":"J. Neurochem."},{"key":"e_1_2_5_9_1","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nrg1828","article-title":"Human monogenic disorders \u2013 a source of novel drug targets","volume":"7","author":"Brinkman R.R.","year":"2006","journal-title":"Nat. Rev. Genet."},{"key":"e_1_2_5_10_1","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.ajhg.2021.03.011","article-title":"30\u2009years of repeat expansion disorders: what have we learned and what are the remaining challenges?","volume":"108","author":"Depienne C.","year":"2021","journal-title":"Am. J. Hum. Genet."},{"key":"e_1_2_5_11_1","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1177\/18796397251337000","article-title":"Huntington's disease clinical trials update: march 2025","volume":"14","author":"Farag M.","year":"2025","journal-title":"J. Huntingt. Dis."},{"key":"e_1_2_5_12_1","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252312485","article-title":"Advances and challenges in gene therapy for neurodegenerative diseases: a systematic review","volume":"25","author":"Garc\u00eda\u2010Gonz\u00e1lez N.","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"e_1_2_5_13_1","first-page":"289","article-title":"Preclinical progression of neurodegenerative diseases","volume":"80","author":"Katsuno M.","year":"2018","journal-title":"Nagoya J. Med. Sci."},{"key":"e_1_2_5_14_1","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/d41586-021-01177-7","article-title":"Failure of genetic therapies for Huntington's devastates community","volume":"593","author":"Kwon D.","year":"2021","journal-title":"Nature"},{"key":"e_1_2_5_15_1","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1080\/14728214.2021.1998452","article-title":"Designing phase II clinical trials in Friedreich ataxia","volume":"26","author":"Rodden L.N.","year":"2021","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"e_1_2_5_16_1","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/S1474-4422(21)00064-8","article-title":"Lessons for clinical trial design in Friedreich's ataxia","volume":"20","author":"Savelieff M.G.","year":"2021","journal-title":"Lancet Neurol."},{"key":"e_1_2_5_17_1","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.ymthe.2021.01.001","article-title":"The path to Progress preclinical studies of age\u2010related neurodegenerative diseases: a perspective on rodent and hiPSC\u2010derived models","volume":"29","author":"MacDougall G.","year":"2021","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"e_1_2_5_18_1","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/14737159.2026.2642712","article-title":"Challenges facing genetic diagnostics of Huntington's disease: an update","volume":"26","author":"Arning L.","year":"2026","journal-title":"Expert Rev. Mol. Diagn."},{"key":"e_1_2_5_19_1","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1002\/cpt.3341","article-title":"Advances in clinical therapies for Huntington's disease and the promise of multi\u2010targeted\/functional drugs based on Clinicaltrials.Gov","volume":"116","author":"Huang C.","year":"2024","journal-title":"Clin. Pharmacol. Ther."},{"key":"e_1_2_5_20_1","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3233\/JHD-170245","article-title":"Fifteen years of clinical trials in Huntington's disease: a very Low clinical drug development success rate","volume":"6","author":"Travessa A.M.","year":"2017","journal-title":"J. Huntington's Dis."},{"key":"e_1_2_5_21_1","doi-asserted-by":"crossref","first-page":"867","DOI":"10.2174\/1570159X21666230216104621","article-title":"The emerging landscape of natural small\u2010molecule therapeutics for Huntington's disease","volume":"21","author":"Bhat S.A.","year":"2023","journal-title":"Curr. Neuropharmacol."},{"key":"e_1_2_5_22_1","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMoa1900907","article-title":"Targeting huntingtin expression in patients with Huntington's disease","volume":"380","author":"Tabrizi S.J.","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"e_1_2_5_23_1","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1056\/NEJMc2300400","article-title":"Tominersen in adults with manifest Huntington's disease","volume":"389","author":"McColgan P.","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"e_1_2_5_24_1","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3233\/JHD-189001","article-title":"Huntington's disease clinical trials corner: February 2018","volume":"7","author":"Rodrigues F.B.","year":"2018","journal-title":"J. Huntington's Dis."},{"key":"e_1_2_5_25_1","unstructured":"Wave Life Sciences Provides Update on Phase 1b\/2a PRECISION\u2010HD Trials \u2013 Wave Life Sciences<https:\/\/ir.wavelifesciences.com\/news\u2010releases\/news\u2010release\u2010details\/wave\u2010life\u2010sciences\u2010provides\u2010update\u2010phase\u20101b2a\u2010precision\u2010hd>."},{"key":"e_1_2_5_26_1","unstructured":"Branaplam\u2009: VIBRANT\u2010HD Study UpdateNovartis<https:\/\/www.novartis.com\/news\/branaplam\u2010vibrant\u2010hd\u2010study\u2010update>."},{"key":"e_1_2_5_27_1","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1038\/s41591-025-03920-3","article-title":"Pridopidine in early\u2010stage manifest Huntington's disease: a phase 3 trial","volume":"31","author":"Reilmann R.","year":"2025","journal-title":"Nat. Med."},{"key":"e_1_2_5_28_1","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1212\/WNL.0000000000004209","article-title":"The CREST\u2010E study of creatine for Huntington disease: a randomized controlled trial","volume":"89","author":"Hersch S.M.","year":"2017","journal-title":"Neurology"},{"key":"e_1_2_5_29_1","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1212\/WNL.0000000000003478","article-title":"A randomized, double\u2010blind, placebo\u2010controlled trial of coenzyme Q10 in Huntington disease","volume":"88","author":"McGarry A.","year":"2017","journal-title":"Neurology"},{"key":"e_1_2_5_30_1","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1002\/mds.23236","article-title":"A futility study of minocycline in Huntington's disease","volume":"25","author":"Huntington Study Group DOMINO Investigators","year":"2010","journal-title":"Mov. Disord."},{"key":"e_1_2_5_31_1","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S1474-4422(23)00454-4","article-title":"Safety and efficacy of laquinimod for Huntington's disease (LEGATO\u2010HD): a multicentre, randomised, double\u2010blind, placebo\u2010controlled, phase 2 study","volume":"23","author":"Reilmann R.","year":"2024","journal-title":"Lancet Neurol."},{"key":"e_1_2_5_32_1","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/s41419-025-08154-2","article-title":"Molecular hallmarks of neurodegeneration in polyglutamine spinocerebellar ataxias","volume":"16","author":"N\u00f3brega C.","year":"2025","journal-title":"Cell Death Dis."},{"key":"e_1_2_5_33_1","volume-title":"StatPearls","author":"Bhandari J.","year":"2026"},{"key":"e_1_2_5_34_1","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/s40120-024-00625-6","article-title":"Video\u2010based kinematic analysis of movement quality in a phase 3 clinical trial of Troriluzole in adults with spinocerebellar ataxia: a post hoc analysis","volume":"13","author":"L'Italien G.J.","year":"2024","journal-title":"Neurol. Ther."},{"key":"e_1_2_5_35_1","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/mds.29255","article-title":"Temporal dynamics of the scale for the assessment and rating of ataxia in spinocerebellar ataxias","volume":"38","author":"Moulaire P.","year":"2023","journal-title":"Mov. Disord."},{"key":"e_1_2_5_36_1","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1002\/acn3.51370","article-title":"Spinocerebellar ataxia clinical trials: opportunities and challenges","volume":"8","author":"Brooker S.M.","year":"2021","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"e_1_2_5_37_1","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S1474-4422(21)00457-9","article-title":"Safety and efficacy of riluzole in spinocerebellar ataxia type 2 in France (ATRIL): a multicentre, randomised, double\u2010blind, placebo\u2010controlled trial","volume":"21","author":"Coarelli G.","year":"2022","journal-title":"Lancet Neurol."},{"key":"e_1_2_5_38_1","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1080\/14737175.2025.2600615","article-title":"Managing symptoms and improving the quality of life of persons with Machado\u2010Joseph disease","volume":"26","author":"Paulino L.A.","year":"2026","journal-title":"Expert Rev. Neurother."},{"key":"e_1_2_5_39_1","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/mds.25803","article-title":"A randomized, phase 2 clinical trial of lithium carbonate in Machado\u2010Joseph disease","volume":"29","author":"Saute J.A.M.","year":"2014","journal-title":"Mov. Disord."},{"key":"e_1_2_5_40_1","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1212\/WNL.0b013e318247cc7a","article-title":"A randomized trial of varenicline (Chantix) for the treatment of spinocerebellar ataxia type 3","volume":"78","author":"Zesiewicz T.A.","year":"2012","journal-title":"Neurology"},{"key":"e_1_2_5_41_1","volume-title":"GeneReviews\u00ae","author":"Cleary J.D.","year":"1993"},{"key":"e_1_2_5_42_1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12883-017-1009-9","article-title":"Frequency of SCA8, SCA10, SCA12, SCA36, FXTAS and C9orf72 repeat expansions in SCA patients negative for the most common SCA subtypes","volume":"18","author":"Aydin G.","year":"2018","journal-title":"BMC Neurol."},{"key":"e_1_2_5_43_1","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/ana.10048","article-title":"Molecular and clinical correlation in five Indian families with spinocerebellar ataxia 12","volume":"50","author":"Srivastava A.K.","year":"2001","journal-title":"Ann. Neurol."},{"key":"e_1_2_5_44_1","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.neures.2012.03.002","article-title":"Identification and quantification of differentially expressed proteins in plasma of spinocerebellar ataxia type 12","volume":"73","author":"Swarup V.","year":"2012","journal-title":"Neurosci. Res."},{"key":"e_1_2_5_45_1","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1007\/s00415-020-10218-6","article-title":"DRPLA: understanding the natural history and developing biomarkers to accelerate therapeutic trials in a globally rare repeat expansion disorder","volume":"268","author":"Chaudhry A.","year":"2021","journal-title":"J. Neurol."},{"key":"e_1_2_5_46_1","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241613021","article-title":"From pathogenesis to therapeutics: a review of 150\u2009years of Huntington's disease research","volume":"24","author":"Jiang A.","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"e_1_2_5_47_1","article-title":"From discovery to innovative translational approaches in 80\u2009years of fragile X syndrome research","volume":"13","author":"Lei M.B.","year":"2025","journal-title":"Biomedicine"},{"key":"e_1_2_5_48_1","unstructured":"Home | ClinicalTrials.gov<https:\/\/clinicaltrials.gov\/>."},{"key":"e_1_2_5_49_1","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21124391","article-title":"Fragile X\u2010associated tremor\/ataxia syndrome (FXTAS): pathophysiology and clinical implications","volume":"21","author":"Cabal\u2010Herrera A.M.","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"e_1_2_5_50_1","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/JCP.0000000000001553","article-title":"Central nervous system trial failures: using the fragile X syndrome\u2010mGluR5 drug target to highlight the complexities of translating preclinical discoveries into human trials","volume":"42","author":"Grabb M.C.","year":"2022","journal-title":"J. Clin. Psychopharmacol."},{"key":"e_1_2_5_51_1","doi-asserted-by":"crossref","DOI":"10.1212\/NXG.0000000000200373","article-title":"Clinical trial designs for rare disorders: a scoping review of the effectiveness of pharmacologic interventions in fragile X syndrome","volume":"12","author":"Van Steenbergen A.","year":"2026","journal-title":"Neurol. Genet."},{"key":"e_1_2_5_52_1","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aab4109","article-title":"Mavoglurant in fragile X syndrome: results of two randomized, double\u2010blind, placebo\u2010controlled trials","volume":"8","author":"Berry\u2010Kravis E.","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"e_1_2_5_53_1","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/npp.2017.177","article-title":"Effect of the mGluR5\u2010NAM basimglurant on behavior in adolescents and adults with fragile X syndrome in a randomized, double\u2010blind, placebo\u2010controlled trial: FragXis phase 2 results","volume":"43","author":"Youssef E.A.","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"e_1_2_5_54_1","article-title":"Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial","volume":"4","author":"Berry\u2010Kravis E.M.","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"e_1_2_5_55_1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s11689-016-9181-6","article-title":"Arbaclofen in fragile X syndrome: results of phase 3 trials","volume":"9","author":"Berry\u2010Kravis E.","year":"2017","journal-title":"J. Neurodev. Disord."},{"key":"e_1_2_5_56_1","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s11689-017-9207-8","article-title":"A randomized double\u2010blind, placebo\u2010controlled trial of ganaxolone in children and adolescents with fragile X syndrome","volume":"9","author":"Ligsay A.","year":"2017","journal-title":"J. Neurodev. Disord."},{"key":"e_1_2_5_57_1","doi-asserted-by":"crossref","first-page":"264","DOI":"10.4088\/JCP.13m08546","article-title":"Memantine for fragile X\u2010associated tremor\/ataxia syndrome (FXTAS): a randomized, double\u2010blind, placebo\u2010controlled trial","volume":"75","author":"Seritan A.L.","year":"2014","journal-title":"J. Clin. Psychiatry"},{"key":"e_1_2_5_58_1","doi-asserted-by":"crossref","first-page":"21719","DOI":"10.1038\/srep21719","article-title":"Memantine improves attentional processes in fragile X\u2010associated tremor\/ataxia syndrome: electrophysiological evidence from a randomized controlled trial","volume":"6","author":"Yang J.\u2010C.","year":"2016","journal-title":"Sci. Rep."},{"key":"e_1_2_5_59_1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0225191","article-title":"Open\u2010label pilot clinical trial of citicoline for fragile X\u2010associated tremor\/ataxia syndrome (FXTAS)","volume":"15","author":"Hall D.A.","year":"2020","journal-title":"PLoS One"},{"key":"e_1_2_5_60_1","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1126\/science.271.5254.1423","article-title":"Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion","volume":"271","author":"Campuzano V.","year":"1996","journal-title":"Science"},{"key":"e_1_2_5_61_1","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.pediatrneurol.2025.10.020","article-title":"Friedreich Ataxia","volume":"174","author":"Subramony S.H.","year":"2026","journal-title":"Pediatr. Neurol."},{"key":"e_1_2_5_62_1","doi-asserted-by":"crossref","DOI":"10.1212\/NXG.0000000000200236","article-title":"Friedreich ataxia: an (almost) 30\u2010year history after gene discovery","volume":"11","author":"Pandolfo M.","year":"2025","journal-title":"Neurol. Genet."},{"key":"e_1_2_5_63_1","article-title":"Clinical evidence of interventions assessed in Friedreich ataxia: a systematic review","volume":"3","author":"Jain P.","year":"2022","journal-title":"Ther. Adv. Rare Dis."},{"key":"e_1_2_5_64_1","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1136\/heart.87.4.346","article-title":"Idebenone and reduced cardiac hypertrophy in Friedreich's ataxia","volume":"87","author":"Hausse A.O.","year":"2002","journal-title":"Heart"},{"key":"e_1_2_5_65_1","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1001\/archneurol.2010.168","article-title":"A phase 3, double\u2010blind, placebo\u2010controlled trial of idebenone in friedreich ataxia","volume":"67","author":"Lynch D.R.","year":"2010","journal-title":"Arch. Neurol."},{"key":"e_1_2_5_66_1","unstructured":"PTC Therapeutics Announces Positive Results from Long\u2010Term Treatment Studies and Updates on Regulatory Progress for Vatiquinone Friedreich Ataxia Program | PTC Therapeutics Inc<https:\/\/ir.ptcbio.com\/news\u2010releases\/news\u2010release\u2010details\/ptc\u2010therapeutics\u2010announces\u2010positive\u2010results\u2010long\u2010term\u2010treatment>."},{"key":"e_1_2_5_67_1","unstructured":"PTC Therapeutics Announces Topline Results from Vatiquinone MOVE\u2010FA Registration\u2010Directed Trial | PTC Therapeutics Inc<https:\/\/ir.ptcbio.com\/news\u2010releases\/news\u2010release\u2010details\/ptc\u2010therapeutics\u2010announces\u2010topline\u2010results\u2010vatiquinone\u2010move\u2010fa>."},{"key":"e_1_2_5_68_1","article-title":"FDA denies approval for Friedreich ataxia agent Vatiquinone, citing more efficacy needed","author":"Meglio M.","year":"2025","journal-title":"Neurol. Live"},{"key":"e_1_2_5_69_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/ane.12337","article-title":"Open\u2010label pilot study of interferon gamma\u20101b in Friedreich ataxia","volume":"132","author":"Seyer L.","year":"2015","journal-title":"Acta Neurol. Scand."},{"key":"e_1_2_5_70_1","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/acn3.731","article-title":"Randomized, double\u2010blind, placebo\u2010controlled study of interferon\u2010\u03b3 1b in Friedreich ataxia","volume":"6","author":"Lynch D.R.","year":"2019","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"e_1_2_5_71_1","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/mds.25836","article-title":"Safety and tolerability of carbamylated erythropoietin in Friedreich's ataxia","volume":"29","author":"Boesch S.","year":"2014","journal-title":"Mov. Disord."},{"key":"e_1_2_5_72_1","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1002\/mds.24066","article-title":"Erythropoietin in Friedreich ataxia: no effect on frataxin in a randomized controlled trial","volume":"27","author":"Mariotti C.","year":"2012","journal-title":"Mov. Disord."},{"key":"e_1_2_5_73_1","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1002\/mds.26552","article-title":"Long\u2010term effect of epoetin alfa on clinical and biochemical markers in friedreich ataxia","volume":"31","author":"Sacc\u00e0 F.","year":"2016","journal-title":"Mov. Disord."},{"key":"e_1_2_5_74_1","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1182\/blood-2007-07-102335","article-title":"Redistribution of accumulated cell iron: a modality of chelation with therapeutic implications","volume":"111","author":"Sohn Y.\u2010S.","year":"2008","journal-title":"Blood"},{"key":"e_1_2_5_75_1","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/ana.24248","article-title":"Deferiprone in Friedreich ataxia: a 6\u2010month randomized controlled trial","volume":"76","author":"Pandolfo M.","year":"2014","journal-title":"Ann. Neurol."},{"key":"e_1_2_5_76_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2025.104462","article-title":"Addressing global regulatory challenges in rare disease drug development","volume":"30","author":"Costa E.","year":"2025","journal-title":"Drug Discov. Today"},{"key":"e_1_2_5_77_1","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/cpt.3631","article-title":"Challenges and possible strategies to address them in rare disease drug development: a statistical perspective","volume":"118","author":"Chen J.","year":"2025","journal-title":"Clin. Pharmacol. Ther."},{"key":"e_1_2_5_78_1","unstructured":"Schuck R.Clinical Pharmacology in Drug Development for Rare Diseases."},{"key":"e_1_2_5_79_1","doi-asserted-by":"crossref","DOI":"10.1007\/s44162-025-00099-6","article-title":"Rare diseases: a comprehensive literature review and future directions","volume":"4","author":"Chaudhary A.","year":"2025","journal-title":"J. Rare Dis."},{"key":"e_1_2_5_80_1","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.3390\/biomedinformatics4020073","article-title":"A comprehensive review of the impact of machine learning and omics on rare neurological diseases","volume":"4","author":"Alganmi N.","year":"2024","journal-title":"BioMedInformatics"},{"key":"e_1_2_5_81_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2026.e00921","article-title":"Strategic consensus on the clinical translation of advanced therapies in paediatric rare neurological disorders","volume":"23","author":"Lim N.Y.","year":"2026","journal-title":"Neurotherapeutics"},{"key":"e_1_2_5_82_1","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1002\/mds.29228","article-title":"Prevalence and incidence of Huntington's disease: an updated systematic\u00a0review and meta\u2010analysis","volume":"37","author":"Medina A.","year":"2022","journal-title":"Mov. Disord."},{"key":"e_1_2_5_83_1","doi-asserted-by":"crossref","DOI":"10.1038\/s41572-019-0074-3","article-title":"Spinocerebellar ataxia","volume":"5","author":"Klockgether T.","year":"2019","journal-title":"Nat. Rev. Dis. Primers."},{"key":"e_1_2_5_84_1","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.667420","article-title":"Enroll\u2010HD: an integrated clinical research platform and worldwide observational study for Huntington's disease","volume":"12","author":"Sathe S.","year":"2021","journal-title":"Front. Neurol."},{"key":"e_1_2_5_85_1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/brain\/aww269","article-title":"Clinical behaviour of spinocerebellar ataxia type 12 and intermediate length abnormal CAG repeats in PPP2R2B","volume":"140","author":"Srivastava A.K.","year":"2017","journal-title":"Brain"},{"key":"e_1_2_5_86_1","doi-asserted-by":"crossref","DOI":"10.1093\/brain\/awx122","article-title":"Age of onset in Huntington's disease is influenced by CAG repeat variations in other polyglutamine disease\u2010associated genes","volume":"140","author":"Stuitje G.","year":"2017","journal-title":"Brain J. Neurol."},{"key":"e_1_2_5_87_1","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1093\/brain\/awu174","article-title":"Modulation of the age at onset in spinocerebellar ataxia by CAG tracts in various genes","volume":"137","author":"Tezenas du Montcel S.","year":"2014","journal-title":"Brain J. Neurol."},{"key":"e_1_2_5_88_1","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209503","article-title":"Trial participation in neurodegenerative diseases: barriers and facilitators: a systematic review and meta\u2010analysis","volume":"103","author":"Weemering D.N.","year":"2024","journal-title":"Neurology"},{"key":"e_1_2_5_89_1","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/ana.26713","article-title":"Antisense oligonucleotide silencing reverses abnormal neurochemistry in spinocerebellar ataxia 3 mice","volume":"94","author":"McLoughlin H.S.","year":"2023","journal-title":"Ann. Neurol."},{"key":"e_1_2_5_90_1","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1002\/psp4.70083","article-title":"State\u2010of\u2010the\u2010art on model\u2010informed drug development approaches for pediatric rare diseases","volume":"14","author":"Krishna R.","year":"2025","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"e_1_2_5_91_1","doi-asserted-by":"crossref","DOI":"10.1002\/psp4.70174","article-title":"Population physiologically\u2010based pharmacokinetic modeling to determine ontogeny: a quantitative clinical pharmacology example in pediatric rare disease","volume":"15","author":"Cleary Y.","year":"2026","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"e_1_2_5_92_1","unstructured":"ICH M15 guideline on general principles for model\u2010informed drug development \u2013 Scientific guideline | European Medicines Agency (EMA)<https:\/\/www.ema.europa.eu\/en\/ich\u2010m15\u2010guideline\u2010general\u2010principles\u2010model\u2010informed\u2010drug\u2010development\u2010step\u20102b\u2010scientific\u2010guideline> (2004)."},{"key":"e_1_2_5_93_1","unstructured":"M15 General Principles for Model\u2010Informed Drug Development | FDA<https:\/\/www.fda.gov\/regulatory\u2010information\/search\u2010fda\u2010guidance\u2010documents\/m15\u2010general\u2010principles\u2010model\u2010informed\u2010drug\u2010development>."},{"key":"e_1_2_5_94_1","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/cpt.3096","article-title":"Creating a roadmap to quantitative systems pharmacology\u2010informed rare disease drug development: a workshop report","volume":"115","author":"Bai J.P.F.","year":"2024","journal-title":"Clin. Pharmacol. Ther."},{"key":"e_1_2_5_95_1","unstructured":"Rare Diseases: Considerations for the Development of Drugs and Biological Products<https:\/\/www.fda.gov\/regulatory\u2010information\/search\u2010fda\u2010guidance\u2010documents\/rare\u2010diseases\u2010considerations\u2010development\u2010drugs\u2010and\u2010biological\u2010products> (2024)."},{"key":"e_1_2_5_96_1","first-page":"2646","article-title":"Multi\u2010center National Study of genotype\u2010phenotype correlation and clinical characteristics in children and young adults with Friedreich's ataxia from Serbia","volume":"13","author":"Kovacevic G.","year":"2025","journal-title":"Biomedicine"},{"key":"e_1_2_5_97_1","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.parkreldis.2020.07.024","article-title":"Genotype\u2010phenotype correlation in 667 Chinese families with spinocerebellar ataxia type 3","volume":"78","author":"Du Y.\u2010C.","year":"2020","journal-title":"Parkinsonism Relat. Disord."},{"key":"e_1_2_5_98_1","unstructured":"Horizon Pharma plc Initiates Phase 3 Trial of ACTIMMUNE (interferon gamma\u20101b) for the Treatment of People With Friedreich's Ataxia | FirstWord Pharma<https:\/\/firstwordpharma.com\/story\/2736265>."},{"key":"e_1_2_5_99_1","doi-asserted-by":"crossref","DOI":"10.3390\/healthcare10122459","article-title":"Ataxia rating scales: content analysis by linking to the international classification of functioning, disability and health","volume":"10","author":"Etoom M.","year":"2022","journal-title":"Health"},{"key":"e_1_2_5_100_1","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/mds.28313","article-title":"Assessment of ataxia rating scales and cerebellar functional tests: critique and recommendations","volume":"36","author":"Perez\u2010Lloret S.","year":"2021","journal-title":"Mov. Disord."},{"key":"e_1_2_5_101_1","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2023.1182431","article-title":"Viewpoint: spinocerebellar ataxias as diseases of Purkinje cell dysfunction rather than Purkinje cell loss","volume":"16","author":"Kapfhammer J.P.","year":"2023","journal-title":"Front. Mol. Neurosci."},{"key":"e_1_2_5_102_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s11689-017-9186-9","article-title":"Fragile X targeted pharmacotherapy: lessons learned and future directions","volume":"9","author":"Erickson C.A.","year":"2017","journal-title":"J. Neurodev. Disord."},{"key":"e_1_2_5_103_1","unstructured":"Promising drug for Huntington disease fails in major trial<https:\/\/www.science.org\/content\/article\/promising\u2010drug\u2010huntington\u2010disease\u2010fails\u2010major\u2010trial>."},{"key":"e_1_2_5_104_1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/acn3.660","article-title":"Safety, pharmacodynamics, and potential benefit of omaveloxolone in Friedreich ataxia","volume":"6","author":"Lynch D.R.","year":"2019","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"e_1_2_5_105_1","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/ana.25934","article-title":"Safety and efficacy of Omaveloxolone in Friedreich ataxia (MOXIe study)","volume":"89","author":"Lynch D.R.","year":"2021","journal-title":"Ann. Neurol."},{"key":"e_1_2_5_106_1","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/mds.29286","article-title":"Efficacy of Omaveloxolone in Friedreich's ataxia: delayed\u2010start analysis of the MOXIe extension","volume":"38","author":"Lynch D.R.","year":"2023","journal-title":"Mov. Disord."},{"key":"e_1_2_5_107_1","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/acn3.51897","article-title":"Propensity matched comparison of omaveloxolone treatment to Friedreich ataxia natural history data","volume":"11","author":"Lynch D.R.","year":"2023","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"e_1_2_5_108_1","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s00702-013-1157-z","article-title":"Downregulation of proteins involved in the endoplasmic reticulum stress response and Nrf2\u2010ARE signaling in lymphoblastoid cells of spinocerebellar ataxia type 17","volume":"121","author":"Lee L.\u2010C.","year":"2014","journal-title":"J. Neural Transm."},{"key":"e_1_2_5_109_1","doi-asserted-by":"crossref","first-page":"986","DOI":"10.18632\/aging.101804","article-title":"Shaoyao Gancao Tang (SG\u2010Tang), a formulated Chinese medicine, reduces aggregation and exerts neuroprotection in spinocerebellar ataxia type 17 (SCA17) cell and mouse models","volume":"11","author":"Chen C.\u2010M.","year":"2019","journal-title":"Aging"},{"key":"e_1_2_5_110_1","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.3390\/antiox11071389","article-title":"In vitro efficacy and molecular mechanism of curcumin analog in pathological regulation of spinocerebellar ataxia type 3","volume":"11","author":"Wu Y.\u2010L.","year":"2022","journal-title":"Antioxidants"},{"key":"e_1_2_5_111_1","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.3390\/antiox13121495","article-title":"Erinacine A\u2010enriched Hericium erinaceus mycelium ethanol extract lessens cellular damage in cell and drosophila models of spinocerebellar ataxia type 3 by improvement of Nrf2 activation","volume":"13","author":"Wu Y.\u2010L.","year":"2024","journal-title":"Antioxidants"},{"key":"e_1_2_5_112_1","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2202-13-86","article-title":"Expanded ataxin\u20107 cause toxicity by inducing ROS production from NADPH oxidase complexes in a stable inducible spinocerebellar ataxia type 7 (SCA7) model","volume":"13","author":"Ajayi A.","year":"2012","journal-title":"BMC Neurosci."},{"key":"e_1_2_5_113_1","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1007\/s11064-013-1229-3","article-title":"From FMRP function to potential therapies for fragile X syndrome","volume":"39","author":"Sethna F.","year":"2014","journal-title":"Neurochem. Res."},{"key":"e_1_2_5_114_1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0057932","article-title":"Impaired mitochondrial dynamics and Nrf2 signaling contribute to compromised responses to oxidative stress in striatal cells expressing full\u2010length mutant huntingtin","volume":"8","author":"Jin Y.N.","year":"2013","journal-title":"PLoS One"},{"key":"e_1_2_5_115_1","doi-asserted-by":"crossref","first-page":"E4676","DOI":"10.1073\/pnas.1614943114","article-title":"KEAP1\u2010modifying small molecule reveals muted NRF2 signaling responses in neural stem cells from Huntington's disease patients","volume":"114","author":"Quinti L.","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"e_1_2_5_116_1","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/S1474-4422(20)30143-5","article-title":"Biological and clinical characteristics of gene carriers far from predicted onset in the Huntington's disease young adult study (HD\u2010YAS): a cross\u2010sectional analysis","volume":"19","author":"Scahill R.I.","year":"2020","journal-title":"Lancet Neurol."},{"key":"e_1_2_5_117_1","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201911803","article-title":"Neurofilaments in spinocerebellar ataxia type 3: blood biomarkers at the preataxic and ataxic stage in humans and mice","volume":"12","author":"Wilke C.","year":"2020","journal-title":"EMBO Mol. Med."},{"key":"e_1_2_5_118_1","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1007\/s12311-023-01608-3","article-title":"Using smartphone sensors for ataxia trials: consensus guidance by the ataxia global initiative working group on digital\u2010motor biomarkers","volume":"23","author":"N\u00e9meth A.H.","year":"2024","journal-title":"Cerebellum"},{"key":"e_1_2_5_119_1","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.gaitpost.2022.07.256","article-title":"mVEGAS \u2013 mobile smartphone\u2010based spatiotemporal gait analysis in healthy and ataxic gait disorders","volume":"97","author":"Ippisch R.","year":"2022","journal-title":"Gait Posture"},{"key":"e_1_2_5_120_1","doi-asserted-by":"crossref","DOI":"10.2196\/32997","article-title":"A remote digital monitoring platform to assess cognitive and motor symptoms in Huntington disease: cross\u2010sectional validation study","volume":"24","author":"Lipsmeier F.","year":"2022","journal-title":"J. Med. Internet Res."},{"key":"e_1_2_5_121_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jclinepi.2020.04.025","article-title":"An overview of platform trials with a checklist for clinical readers","volume":"125","author":"Park J.J.H.","year":"2020","journal-title":"J. Clin. Epidemiol."},{"key":"e_1_2_5_122_1","doi-asserted-by":"crossref","first-page":"5267","DOI":"10.3390\/jcm14155267","article-title":"Adaptive Bayesian clinical trials: the past, present, and future of clinical research","volume":"14","author":"Berry D.A.","year":"2025","journal-title":"J. Clin. Med."},{"key":"e_1_2_5_123_1","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ymthe.2016.11.010","article-title":"CRISPR\/Cas9 editing of the mutant huntingtin allele in\u00a0vitro and in\u00a0vivo","volume":"25","author":"Monteys A.M.","year":"2017","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"e_1_2_5_124_1","unstructured":"ElevateBio Life Edit: Opening New Frontiers In Genomic Medicine<https:\/\/www.cellandgene.com\/doc\/elevatebio\u2010life\u2010edit\u2010opening\u2010new\u2010frontiers\u2010in\u2010genomic\u2010medicine\u20100001>."},{"key":"e_1_2_5_125_1","doi-asserted-by":"crossref","DOI":"10.1111\/jnc.70395","article-title":"Brain organoids as emerging platforms\u00a0for modeling neurodegenerative diseases: Progress, challenges, and future directions","volume":"170","author":"Kaya Y.","year":"2026","journal-title":"J. Neurochem."},{"key":"e_1_2_5_126_1","first-page":"7","article-title":"Fragile X syndrome: lessons learned from the Most translated neurodevelopmental disorder in clinical trials","volume":"8","author":"Duy P.Q.","year":"2017","journal-title":"Transl. Neurosci."}],"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.70445","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cpt.70445","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.70445","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T05:59:38Z","timestamp":1786946378000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt.70445"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,16]]},"references-count":126,"alternative-id":["10.1002\/cpt.70445"],"URL":"https:\/\/doi.org\/10.1002\/cpt.70445","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,16]]},"assertion":[{"value":"2026-04-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"cpt.70445"}}